Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vesuvius FY profits drop amid 'difficult' market conditions

(Sharecast News) - Molten metal flow engineer Vesuvius reported a drop in full-year profit and revenue on Thursday amid "difficult" market conditions. In the year to the end of December 2023, pre-tax profit fell 13.2% to £179.4m, with revenue down to £1.9bn from £2.0bn a year earlier. This reflected lower volumes in a weaker market, partially offset by good pricing performance and market share gains in Flow Control and Foundry, Vesuvius said.

Vesuvius said that after some limited improvement in the first half from the very low level of H2 2022, its steel markets weakened again in the second half of 2023. This was particularly pronounced in Europe, where steel production fell by 7.3% in 2023 compared with the previous year, and was 5% below the worst year of the pandemic in 2020.

The company proposed a final dividend of 16.2p a share, taking the full-year dividend to 23p, up 3.4%.

Chief executive Patrick Andre said: "Despite the short-term uncertainties in our end steel and foundry markets, we remain confident in the mid to long term growth potential of these markets and in particular the steel market outside of China, which should be a tailwind for us.

"The strength of our technology-based business model should also enable us to continue simultaneously outperform our underlying markets in Flow Control and Foundry and maintain a positive pricing performance for all our business units in the coming years.

"This, coupled with our relentless drive to optimise our cost base as illustrated by the launch of our new cost optimisation programme, positions us very well to achieve our objectives of 12.5% return on sales by 2026 and free cash flow generation of £400m over the next three years."

Share this article

Related Sharecast Articles

Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.
McCarthy out, Adshead in as Ultimate Products chair
(Sharecast News) - Ultimate Products, the parent of homeware brands including Salter and Beldray, announced a change in its leadership on Monday, with James 'Jim' McCarthy deciding to step down as non-executive chair from 31 July.
Digital 9 to make additional revolving credit facility repayment
(Sharecast News) - Infrastructure company Digital 9 Infrastructure announced a significant step towards strengthening its financial position on Monday, with the receipt of a deferred consideration payment of $25m (£20m) related to the sale of the Verne Global group, as announced on 15 March.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.